Tectonic Therapeutic reports positive Phase 1b Part B data for TX45 in PH-HFrEF

Tectonic Therapeutic, Inc.

Single dose of TX45 improved left heart function and pulmonary hemodynamics: PCWP -29.2%, CO +17.3%, mPAP -19.3%, TPR -29.2% mean change.
In CpcPH patients (PVR>3 WU), PVR reduced -19.7%; PVR >2 WU group showed -10.3% mean change.
Echocardiographic improvements at day 29: LVEF +19.4%, RVFAC +20.3%, TAPSE/SPAP +36.3% mean change.
TX45 well tolerated with no serious or severe adverse events, no clinically significant BP changes or immune reactions.
APEX Phase 2 trial in PH-HFpEF ongoing; topline results expected in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.